Current Report Filing (8-k)
September 12 2016 - 9:13AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 8, 2016
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-16467
|
|
33-0303583
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S
Employer
Identification
No.)
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01 Regulation FD Disclosure
On
September 8, 2016, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s President and
Chief Executive Officer, James S. Manuso, Ph.D., will be presenting at the Rodman & Renshaw 18th Annual Global Investment
Conference at the Lotte New York Palace Hotel in New York, New York. Dr. Manuso is currently scheduled to present at 4:15 p.m.
Eastern Time on Monday, September 12, 2016.
Dr.
Manuso will present the Company's top-line data from its Phase 2A clinical trial of its proprietary orally administered ampakine,
CX1739, conducted at the Duke University School of Medicine, which was determined to be safe and well tolerated and antagonized
the respiratory depressive effects of remifentanil, a potent opioid. Dr. Manuso will also present the Company’s upcoming
clinical initiatives with ampakines for central sleep apnea (Phase 2B) and spinal cord injury. Dr. Manuso will provide an update
on dronabinol for obstructive sleep apnea (Phase 2B).
The
slide presentation that the Company will be using at the conference is attached as Exhibit 99.1 and is being furnished and not
filed pursuant to Item 7.01 of Form 8-K. The presentation will be available by live webcast that can be accessed
http://wsw.com/webcast/rrshq26/rspi
.
The presentation and slides will be accessible after the presentation by clicking on the investors tab on the RespireRx web-site
at
www.respirerx.com
and following the links and instructions.
The
press release announcing the Company’s participation in the conference is attached as Exhibit 99.2. A subsequent press release,
dated September 12, 2016, announcing preliminary, top-line results of the Company’s recently concluded Phase 2A clinical
trial testing the impact of CX1739 on opioid-induced respiratory depression, is also attached as Exhibit 99.3.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere
in this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
RESPIRERX
PHARMACEUTICALS INC.
|
Date:
September 12, 2016
|
|
|
|
By:
|
/s/
James S. Manuso
|
|
|
James
S. Manuso
|
|
|
President
and Chief Executive Officer
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Exhibit
Description
|
99.1
|
|
Slide
Presentation*
|
99.2
|
|
Press
Release dated September 8, 2016*
|
99.3
|
|
Press
Release dated September 12, 2016*
|
*
Furnished herewith.
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024